Precision BioSciences to Present at the Annual J.P. Morgan Healthcare Conference
04 janv. 2021 07h00 HE
|
Precision Biosciences
DURHAM, N.C., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS®...
Precision BioSciences Announces Executive Leadership Change
14 déc. 2020 00h00 HE
|
Precision Biosciences
DURHAM, N.C., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS®...
Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R B-cell Acute Lymphoblastic Leukemia (B-ALL)
04 déc. 2020 06h30 HE
|
Precision Biosciences
Acceptable Tolerability and Safety Profile in 27 Patients with No Graft versus Host Disease (GvHD), No Grade ≥ 3 Cytokine Release Syndrome (CRS), and No Grade ≥ 3 Neurotoxicity (ICANS) PBCAR0191...
Precision BioSciences to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
24 nov. 2020 16h05 HE
|
Precision Biosciences
DURHAM, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS®...
Precision BioSciences Reports Third Quarter 2020 Financial Results and Provides Business Update
10 nov. 2020 07h00 HE
|
Precision Biosciences
Expanded allogeneic CAR T development collaboration with Servier to include four new programs targeting hematological and solid tumors Advanced CAR T clinical pipeline, including a clinical...
Precision BioSciences to Report Third Quarter 2020 Financial Results on November 10, 2020
03 nov. 2020 07h00 HE
|
Precision Biosciences
DURHAM, N.C., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS®...
Precision BioSciences Announces U.S. Patent Trial and Appeal Board Upholds Allogeneic CAR T Patents
15 oct. 2020 07h00 HE
|
Precision Biosciences
DURHAM, N.C., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies...
Precision BioSciences Appoints Alex Kelly as Chief Corporate Affairs Officer
14 oct. 2020 07h00 HE
|
Precision Biosciences
DURHAM, N.C., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies...
Precision BioSciences to Present at Upcoming Virtual Investor Conferences in October
28 sept. 2020 07h00 HE
|
Precision Biosciences
DURHAM, N.C., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies...
Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma
21 sept. 2020 07h00 HE
|
Precision Biosciences
DURHAM, N.C. and STAMFORD, Conn., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology developing allogeneic CAR T and in vivo gene...